Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC12A2 | P55011 | 1/20 | 0.39 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3641091 | 1.00 | SLC12A2 (0.39) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL8154423 | 1.00 | SLC12A2 (0.39) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL3641089 | 1.00 | SLC12A2 (0.39) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL7269764 | 1.00 | SLC12A2 (0.39) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL9334967 | 0.91 | SLC12A2 (0.37) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL18729643 | 0.89 | SLC12A2 (0.39) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL9626662 | 0.88 | SLC12A2 (0.37) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL27032127 | 0.88 | SLC12A2 (0.37) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL27130489 | 0.88 | SLC12A2 (0.37) | SLC12A2SLC12A5TP53TSHRHTT | |
| SCHEMBL27031979 | 0.88 | SLC12A2 (0.37) | SLC12A2SLC12A5TP53TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895167-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-12-05 | — | — | EP | disclosed |
| US-9216965-B2 | Amino-quinolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-9216965-B2 | Amino-quinolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-9216965-B2 | Amino-quinolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-22 | — | — | US | disclosed |
| US-9187450-B2 | Substituted pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| EP-2592076-B1 | SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20150094333-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20150094333-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20150094333-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20140213549-A9 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20130109653-A1 | Substituted Pyridine Compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA, LLC (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157657-A1 | DEUTERIUM-ENRICHED TENOFOVIR | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-6653296-B1 | 2-phosphonomethoxypropyl derivatives of purine and pyrimidine bases | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-11-25 | — | — | US | disclosed |
| US-6057305-A | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2000-05-02 | — | — | US | disclosed |
| EP-0897917-A1 | Compounds for use in the preparation of antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1999-02-24 | — | — | EP | disclosed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094333-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | MAP3K3, ABL1, MAP3K20 | SLC12A2 3939/4885SLC12A5 3858/4885TP53 1003/4885 |
| US-20140213549-A9 | Substituted Pyridine Compound | CETP, MTTP, PRCP | SLC12A2 1543/4885SLC12A5 1120/4885TP53 3244/4885 |
| US-20080318904-A1 | DEUTERIUM-ENRICHED TENOFOVIR | DCTD, SAMHD1, SLC28A1 | SLC12A2 609/4885SLC12A5 481/4885TP53 2228/4885 |
| US-20090105208-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | SLC12A2 2195/4885SLC12A5 2164/4885TP53 4048/4885 |
| US-20130109653-A1 | Substituted Pyridine Compound | CETP, MTTP, PRCP | SLC12A2 1543/4885SLC12A5 1120/4885TP53 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.